ItInsightsWorld AIapplications: Measuring Claude in Drug Development Workflows

For leaders evaluating AI applications, the drug development programs described by Anthropic are useful because they show where Claude enters real workflows rather than staying as a demo. Over the past several months, six organizations were selected for deep research partnerships, and the resulting work covers target discovery, molecule design, optimization, manufacturing paperwork, filings, company creation, and clinical trial planning. The value signal is not one headline model upgrade. It is repeated evidence that AI can shorten cycles, expose hidden quality risks, and expand what small teams can operate.

Why this AI application pattern matters for life sciences

Drug development is a chain of decisions, documents, experiments, and regulatory evidence. A single model output rarely changes the chain. The reported programs treat Claude as a workflow participant that can translate objectives, generate candidate designs, analyze data, flag document risk, or assemble operational artifacts. That framing helps teams decide where pilots should begin: where tasks are repeated, measurable, and bounded by review.

Anthropic describes this strategy as serving three ways. It clarifies model strengths and limits across more tasks, creates case studies for the wider life sciences community, and may produce direct impact for diseases such as food allergies, rare childhood diseases, and several forms of cancer. The same logic can guide enterprise adoption: choose application domains where business process, evaluation method, and governance are already explicit.

Workflow map before implementation

Development layer	What AI is doing	Practical signal	Human gate needed
Target and modality discovery	Assess whether a target is worth pursuing	Pleiades first skill evaluated on 45 target-disease pairs	Scientific prioritization and capital allocation
Molecule and therapy design	Generate variants, edit genetic instruction regions, propose candidates	One design was about 70% shorter than the standard version	Laboratory synthesis and functional testing
Lead optimization	Improve binding, stability, and aggregation behavior	Best versions bound more than 10x more tightly	Purification, assay interpretation, and formulation review
Manufacturing records and filings	Flag documentation issues and draft regulatory text	Claude caught all 11 issues human reviewers found	Quality ownership and regulatory signoff
Clinical trial planning	Analyze proprietary data, create study plans, estimate success likelihood	Early-stage BMS work planned to expand in 2027	Clinical governance, privacy, and portfolio review

Case evidence: what each program showed

Generate Biomedicines: engineering a therapy modality

Generate Biomedicines is working to make CAR T-cell therapy useful for solid tumor cancers, not only blood cell cancers. The team changed one part of the therapy’s genetic instructions, creating room for additional instructions suited to other cancer types. Six Generate scientists used Claude Code to propose new designs. One design was about 70% shorter than the standard version, and lab tests found it more effective: immune cells made roughly 10 times as many receptors, killed tumor cells more efficiently, and remained active longer.

Divergence Labs: generating candidate antibodies

Divergence Labs is pursuing food allergies caused by IgE with an antibody strategy that has two arms: one that binds tightly to IgE and another that helps detach IgE from immune cells. Claude translated program goals into a detailed design plan, then largely autonomously generated roughly 35,000 antibody designs in about a month for narrowing and testing. Early work found three designs that could bind to IgE and 20 that could dislodge it. Three of those 20 appeared to dislodge IgE more effectively than the standard medication.

BigHat Biosciences: optimizing leads

BigHat Biosciences uses AI and an automated lab to improve potential drugs called leads. The relevant checks are tight target binding, stability through manufacturing and storage, and avoidance of clumping, and Claude supported these three properties in two leads. Connected to Reccy, BigHat’s lab data system, Claude proposed molecule changes, and about 1,010 variants were made and tested in about 10 weeks. When standard heat-stability and clumping metrics appeared misleading, Claude and an Anthropic researcher reanalyzed raw data, proposed different metrics and a protocol change, and the team validated the main predictions. Compared with originals, the best versions bound more than 10x more tightly, the cancer-targeting lead stayed in solution 18°C higher, and the longer-lasting lead clumped more than 100x more slowly.

Enveda: manufacturing and filings

Clinical trials require manufacturing records showing each drug batch meets strict quality standards, plus regulatory filings. At Enveda, manufacturing chemists spent up to 75% of their time on paperwork. Enveda connected its manufacturing documents to Claude and used it to flag possible issues. Across 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted and flagged seven they’d missed. Human review time fell by 89%, from over 25 hours to less than three. Separately, Claude produced first drafts of two important regulatory documents; one took four hours, compared with about three months by hand, and human review found one minor error in the other.

The Column Group: company creation

The Column Group, or TCG, is testing whether AI can reduce both scientific work and administrative overhead for biotechnology creation. It is establishing Pleiades, a company that will use Claude to run many more and more complex drug programs than a small team usually could. This could change investment logic by making ambitious programs less costly to start. Pleiades is developing new Claude tools and workflows, and its first skill for assessing drug targets has been evaluated on 45 target-disease pairs.

Bristol Myers Squibb: clinical trial planning

Anthropic recently began work with Bristol Myers Squibb to find and address bottlenecks in clinical trial planning. BMS is using Claude to assess plans for an early-stage drug in clinical trials and estimate the likelihood of trial success. Together, the teams plan to expand this work in 2027 to understand its potential for increasing early-development success probability.

We use Claude at the clinical trial stage to analyze proprietary data, create a clinical study plan, and weigh the study’s chance of success. From a single prompt, Claude generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete. We did all of this while ensuring the security of our highly sensitive data. We look forward to expanding this work across our pipeline to support portfolio-level decisions.

Michael Pourdehnad

Mithril Medicine: rare disease research

Mithril Medicine is a one-person company developing treatments for two rare forms of muscular dystrophy. Its founder, Cody Tranbarger, used Claude to organize contracts, logistics, and experiments with 11 external labs and delegated many operational aspects to Claude. As a result, Mithril moved a possible treatment from idea to promising mouse results in less than 18 months. After Anthropic acquired the company, Cody continued research, and if candidates hold up, Anthropic expects a drug to be ready to start clinical trials in humans as soon as late 2028.

Implementation checklist for AI leaders

• Start from a workflow bottleneck that has clear inputs, outputs, and review owners.
• Choose an application area where time, cost, or quality metrics are measurable.
• Define whether Claude will generate options, rank evidence, draft documents, connect to data systems, or coordinate partners.
• Require experimental validation before design candidates become program decisions.
• Keep human regulatory and quality accountability for filings, batches, and trial plans.
• Protect sensitive data and proprietary records while enabling useful tool access.
• Track cycle time, error detection, review time, and downstream adoption cost.
• Plan pilot-to-production handoffs with versioned prompts, data lineage, and exception handling.

Step-by-step path to use AI application lessons in your own program

1. Inventory the process chain. Split discovery, design, optimization, manufacturing documentation, filings, and clinical planning into discrete steps.
2. Select one measurable pain point. Good candidates are long document review, repetitive candidate generation, or fragmented experiment coordination.
3. Define evaluation criteria before running pilots. For molecules, ask for binding, stability, aggregation, and biological effect; for filings, ask for error detection and review time.
4. Connect only approved data and tools. Reccy-like lab systems, document repositories, and design spaces should be governed.
5. Run a bounded generation-and-test loop. Produce candidate outputs, rank them, synthesize or validate a subset, then revise.
6. Escalate metrics disputes to raw-data review. BigHat’s heat-stability and clumping example shows that changing metrics can unlock progress.
7. Document human decisions. Regulatory and clinical stages require accountable signoff, audit trails, and model limitation notes.
8. Expand only after evidence. Move from a single task to adjacent workflow steps once quality, security, and value are demonstrated.

Common pitfalls when adapting these programs

• Treating AI as a single problem solver when bottlenecks are distributed across the drug development process.
• Scaling model capability before validating outputs in the lab, document system, or clinical review environment.
• Focusing on the number of generated designs without checking whether they satisfy functional properties.
• Using legacy metrics as the only success signal when the metric itself may be misleading.
• Ignoring administrative burden, contracts, logistics, and filing requirements that slow small teams.
• Assuming preclinical progress equals clinical readiness; most reported programs remain early and mostly preclinical.

FAQ

What does this program set tell business leaders?

It shows that AI can be embedded in several separate business workflows, not only molecule proposal. The strongest practical lesson is to connect model outputs to tests, documents, data systems, and decision reviews.

Where is AI already showing value?

In design variation, lead optimization, documentation review, drafting, and early clinical planning. Reported results include shorter designs, more receptors, better binding and stability metrics, lower review time, and faster drafting.

What should teams avoid?

Do not treat early AI output as validated medical evidence. Most work described is early stage and mostly preclinical. Human scientific, quality, privacy, and regulatory review remains essential.

What comes next?

Anthropic plans to extend Claude’s role into clinical trials as programs advance and to partner with organizations already at clinical stage. It has also rolled out Claude Science, provided Claude credits for life scientists, created the Life Sciences Verification Program, and launched an open call for guest investigators.

Action advice: how to apply the reported lessons now

For enterprise teams, the recommended first action is a workflow audit, not a model audit. Rank candidate AI application areas by cycle length, document volume, review friction, data availability, and error tolerance. Then run pilots with measurable stop conditions.

For product and operations leaders, pair model work with a review interface that exposes assumptions, metrics, and unresolved items. For solution architects, make integration with controlled data systems a first-class requirement. For regulatory owners, define what human evidence is required before AI-generated text or analysis can support a decision.

Published details include partner technical reports and preprints describing thought process, methods, and early results. If your organization wants to evaluate the value of a Claude-based life sciences application, choose the workflow where measurement is hardest to argue with: time removed, errors found, designs tested, or decisions made clearer.